EVALUATION OF SERUM IRON PROFILE IN BETA THALASSEMIA PATIENTS
DOI:
https://doi.org/10.71000/ykgchy44Keywords:
Beta-thalassemia, Chelation therapy, Hemoglobin, Iron overload, Pakistan, Serum ferritin, TransfusionsAbstract
Background: Beta-thalassemia is an inherited hemoglobinopathy caused by mutations in the beta-globin gene, resulting in reduced or absent beta-globin chain synthesis. The imbalance in globin chains leads to ineffective erythropoiesis and severe anemia, especially in transfusion-dependent individuals. In regions like Pakistan, where the carrier frequency is high, regular blood transfusions are essential for survival in beta-thalassemia major patients. However, repeated transfusions contribute to progressive iron overload, making timely monitoring and management crucial. Serum ferritin serves as a simple, noninvasive, and cost-effective biomarker for assessing iron burden.
Objective: To evaluate the serum iron profile and transfusion frequency among beta-thalassemia major patients.
Methods: This cross-sectional study included 100 electrophoresis-confirmed beta-thalassemia major patients aged 2 to 19 years, admitted at Alkhidmat Thalassemia Care Centre, Lahore. Blood samples (2–3 mL) were collected using gel separator vials. Serum ferritin levels were analyzed using both manual ELISA and automated chemiluminescence immunoassays. Hemoglobin levels and the number of lifetime transfusions were also recorded. Data were analyzed using SPSS version 17.0.
Results: Among 100 patients, 55 were male (55%) and 45 female (45%), with a mean age of 9.68 ± 4.843 years. The average number of transfusions was 92.92 ± 34.677. Mean serum ferritin concentration was 2376.72 ± 749.03 ng/mL. Ferritin levels were <1500 ng/mL in 3 patients (3%), 1500–2500 ng/mL in 64 patients (64%), and >2500 ng/mL in 33 patients (33%). Mean hemoglobin concentration was 7.208 ± 0.7062 g/dL.
Conclusion: Serum ferritin remains an accessible and reliable indicator of iron overload in beta-thalassemia major patients. The findings underscore the importance of routine monitoring and effective chelation therapy to reduce iron-induced complications, improve quality of life, and guide evidence-based patient care.
References
Needs, T., L.F. Gonzalez-Mosquera, and D.T. Lynch, Beta Thalassemia. 2022: StatPearls Publishing, Treasure Island (FL).
Rabadiya SM, Yogesh M, Nagda J, Gandhi R, Makwana N. Association of serum ferritin trends with liver enzyme patterns in β-thalassemia major: A longitudinal correlational study. J Family Med Prim Care. 2024;13(7):2698-702.
Padhani ZA, Gangwani MK, Sadaf A, Hasan B, Colan S, Alvi N, et al. Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion-dependent beta thalassaemia. Cochrane Database Syst Rev. 2023;11(11):Cd011626.
Darvishi-Khezri H, Naderisorki M, Zahedi M, Mortazavi P, Tajik F, Nasirzadeh A, et al. Coadministration of silymarin with iron chelators in transfusion-dependent β-thalassemia patients: a systematic review and meta-analysis for effect on iron overload. Expert Rev Clin Pharmacol. 2021;14(11):1445-53.
Yusuf S, Herdata HN, Edward ED, Khairunnisa K. Comparison of oral iron chelators in the management of transfusion-dependent β-thalassemia major based on serum ferritin and liver enzymes. F1000Res. 2023;12:154.
Atmakusuma TD, Hasibuan FD, Purnamasari D. The Correlation Between Iron Overload and Endocrine Function in Adult Transfusion-Dependent Beta-Thalassemia Patients with Growth Retardation. J Blood Med. 2021;12:749-53.
Atmakusuma TD, Girson R, Koesnoe S. Correlations between Iron Load and CD4 in Adult Transfusion-Dependent Beta Thalassemia. Anemia. 2021;2021:5549503.
Zulfiqar Z, Kanwal A, Chaudhry M, Aadil M, Qaiser S, Malik A, et al. Cutaneous Manifestations in Patients with Beta-Thalassemia Major. J Mother Child. 2023;27(1):142-6.
Musallam KM, Barella S, Origa R, Ferrero GB, Lisi R, Pasanisi A, et al. Differential effects of iron chelators on iron burden and long-term morbidity and mortality outcomes in a large cohort of transfusion-dependent β-thalassemia patients who remained on the same monotherapy over 10 years. Blood Cells Mol Dis. 2024;107:102859.
Elalfy MS, Hamdy M, Adly A, Ebeid FSE, Temin NT, Rozova A, et al. Efficacy and safety of early-start deferiprone in infants and young children with transfusion-dependent beta thalassemia: Evidence for iron shuttling to transferrin in a randomized, double-blind, placebo-controlled, clinical trial (START). Am J Hematol. 2023;98(9):1415-24.
Sultana I, Sultana N, Rabbany MA, Banu M, Begum S, Alam S, et al. Evaluation of Liver Function Tests in β-Thalassemia Major Children. Mymensingh Med J. 2022;31(4):894-9.
Faruqi A, Zafar T, Subuctageen S, Mughal IA. Iron overload and liver function in patients with beta thalassemia major: A cross sectional study. Pak J Med Sci. 2024;40(9):2000-4.
Daar S, Al-Naamani K, De Sanctis V, Al Rahbi S, Al Zadjali S, Khan H, et al. Mortality and complications in Omani patients with beta-thalassemia major: a long-term follow-up study. Acta Biomed. 2023;94(4):e2023191.
Kurban LA, Almarri BK, Alshamsi MH, Abdelrahman SS, Alwahshi SG, Alhorani Q, et al. Optimized serum ferritin prediction of iron overload in transfusion-dependent thalassemia: likelihood ratio and age-adjustment approach. Ann Saudi Med. 2023;43(2):90-6.
ElLaboudy MA, Saber MM, Adly AA, Ismail EA, Ibrahim FA, Elalfy OM. Oxidative stress markers and tissue iron overload after 12-months vitamin E supplementation for children with transfusion-dependent β-thalassemia on different iron chelators: A randomized placebo-controlled trial. Clin Nutr. 2025;50:154-63.
Eghbali A, Ghaffari K, Shaykh Baygloo R, Eghbali A, Ghasemi A. Polyneuropathy Associated with Age of Starting the Transfusion and Serum Ferritin Level in Iranian Patients with Thalassemia Major and Intermedia. Hemoglobin. 2023;47(2):42-8.
Haghpanah S, Hosseini-Bensenjan M, Sayadi M, Karimi M, de Sanctis V, Ramzi M, et al. The Prevalence of Hypothyroidism among Patients With β-Thalassemia: A Systematic Review and Meta-Analysis of Cross-Sectional Studies. Hemoglobin. 2021;45(5):275-86.
Shah F, Huey K, Deshpande S, Turner M, Chitnis M, Schiller E, et al. Relationship between Serum Ferritin and Outcomes in β-Thalassemia: A Systematic Literature Review. J Clin Med. 2022;11(15).
Musallam KM, Barella S, Origa R, Ferrero GB, Lisi R, Pasanisi A, et al. Revisiting iron overload status and change thresholds as predictors of mortality in transfusion-dependent β-thalassemia: a 10-year cohort study. Ann Hematol. 2024;103(7):2283-97.
Arab-Zozani M, Kheyrandish S, Rastgar A, Miri-Moghaddam E. A Systematic Review and Meta-Analysis of Stature Growth Complications in β-thalassemia Major Patients. Ann Glob Health. 2021;87(1):48.
Susanah, S., et al., Iron status in newly diagnosed β-thalassemia major: High rate of iron status due to erythropoiesis drive. BioMed Research International, 2021. 2021: p. 1-7.
Faranoush, M., et al., Complications in patients with transfusion dependent thalassemia: A descriptive cross‐sectional study. Health Science Reports, 2023. 6(10): p. e1624.
Zekavat OR, Zareian Jahromi M, Haghpanah S, Kargar Jahromi Z, Cohan N. Association of HFE Gene Mutations With Serum Ferritin Level and Heart and Liver Iron Overload in Patients With Transfusion-dependent Beta-Thalassemia. J Pediatr Hematol Oncol. 2021;43(1):e26-e8.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Talha Ahmad, Anas Jahangir, Tayyaba Baloch, Hamza Imtiaz, Muhammad Iqbal, Muhammad Nayyer Shaban, Zarmeen Zahra Ali, Muhammad Zeshan, Asia Jahanzaib , Fatima Ashraf Mughal (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
